EHA 2022 preview – some good news at last

As another terrible week on the Nasdaq biotechnology index draws to a close investors have celebrated some good news at last. Yesterday’s unveiling of abstracts for June’s European Hematology Association brought clinical data that boosted the share prices of several cell therapy-focused biotechs.

Perhaps best received were the first human data for Caribou’s allogeneic Car-T therapy CB-010, sending the depressed group’s stock up 22%. Updates from Gracell and Autolus also struck a chord with the markets, though for many cell therapy groups the big unanswered question remains how durable remissions – and share price uplifts – prove to be.